Arvind Kaimal
Kampala, C, Uganda
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial.
Journal: The Lancet. Infectious diseases
Published: March 17, 2024
Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial.
Journal: The lancet. HIV
Published: March 07, 2022
Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV.
Journal: The New England journal of medicine
Published: July 21, 2021
Calcaneal Quantitative Ultrasonography and Urinary Retinol-Binding Protein in Antiretroviral-Treated Patients With Human Immunodeficiency Virus in Uganda: A Pilot Study.
Journal: The Journal of infectious diseases
Published: January 13, 2020
Evaluation of the Management of Patients with Detectable Viral Load after the Implementation of Routine Viral Load Monitoring in an Urban HIV Clinic in Uganda.
Journal: AIDS research and treatment
Published: April 10, 2019
An observational study in an urban Ugandan clinic comparing virological outcomes of patients switched from first-line antiretroviral regimens to second-line regimens containing ritonavir-boosted atazanavir or ritonavir-boosted lopinavir.
Journal: BMC infectious diseases
Published: February 27, 2018
Strengthening the "Viral Failure Pathway": Clinical Decision and Outcomes of Patients With Confirmed Viral Failure in a Large HIV Care Clinic in Uganda.
Journal: Journal of acquired immune deficiency syndromes (1999)
Published: November 17, 2015
Showing 1-8 of 8
Last Updated: 09/26/2026